{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:14:33Z","timestamp":1785165273636,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s40265-019-01123-y","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T16:40:14Z","timestamp":1557160814000},"page":"785-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Solriamfetol: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"1123_CR1","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals receives new PDUFA goal date for solriamfetol for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea [media release]. 21 Dec 2018. \n                    http:\/\/www.jazzpharmaceuticals.com\n                    \n                  ."},{"key":"1123_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.smrv.2018.09.006","volume":"43","author":"ST Szabo","year":"2019","unstructured":"Szabo ST, Thorpy MJ, Mayer G, et al. Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy. Sleep Med Rev. 2019;43:23\u201336.","journal-title":"Sleep Med Rev."},{"key":"1123_CR3","unstructured":"Jazz Pharmaceuticals. SUNOSI (solriamfetol) tablets: US prescribing information. 2019. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211230s000lbl.pdf\n                    \n                  . Accessed 01 Apr 2019."},{"key":"1123_CR4","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals submits marketing authorization application to European Medicines Agency for solriamfetol as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea [media release]. 09 Nov 2018. \n                    http:\/\/www.jazzpharmaceuticals.com\n                    \n                  ."},{"key":"1123_CR5","unstructured":"SK biopharmaceuticals. SK biopharmaceuticals enters into a collaboration agreement to study Lou Gehrig\u2019s Disease [media release]. 19 Sept 2011. \n                    http:\/\/www.skbp.com\n                    \n                  ."},{"key":"1123_CR6","unstructured":"Addrenex Pharmaceuticals. Addrenex Pharmaceuticals expands product pipeline by licensing new drug to treat narcolepsy [media release]. 13 May 2009. \n                    http:\/\/w.addrenex.com\n                    \n                  ."},{"key":"1123_CR7","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals announces acquisition from Aerial Biopharma of rights to a late stage investigational compound for excessive daytime sleepiness [media release]. 13 Jan 2014. \n                    http:\/\/www.jazzpharmaceuticals.com\n                    \n                  ."},{"key":"1123_CR8","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals announces full year and fourth quarter 2013 financial results [media release]. 25 Feb 2014. \n                    http:\/\/www.jazzpharmaceuticals.com\n                    \n                  ."},{"issue":"2","key":"1123_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1124\/jpet.118.248120","volume":"366","author":"MG Baladi","year":"2018","unstructured":"Baladi MG, Forster MJ, Gatch MB, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367\u201376.","journal-title":"J Pharmacol Exp Ther."},{"issue":"Suppl. 1","key":"1123_CR10","first-page":"S63","volume":"45","author":"K Zomorodi","year":"2018","unstructured":"Zomorodi K, Kassir N, Kheibarshekan L. Population pharmacokinetic analysis of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor [abstract no. T-038]. J Pharmacokinet Pharmacodyn. 2018;45(Suppl. 1):S63.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"1123_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.clinthera.2018.12.001","volume":"41","author":"K Zomorodi","year":"2019","unstructured":"Zomorodi K, Kankam M, Lu Y. A phase I, randomized, crossover, open-label study of the pharmacokinetics of solriamfetol (JZP-110) in healthy adult subjects with and without food. Clin Ther. 2019;41(2):196\u2013204.","journal-title":"Clin Ther."},{"key":"1123_CR12","doi-asserted-by":"crossref","unstructured":"Zomorodi K, Chen D, Lee L, et al. Single-dose pharmacokinetics and safety of solriamfetol in participants with normal or impaired renal function and with end-stage renal disease requiring hemodialysis. J Clin Pharmacol. 2019;1\u201310.","DOI":"10.1002\/jcph.1402"},{"issue":"3","key":"1123_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ana.25423","volume":"85","author":"MJ Thorpy","year":"2019","unstructured":"Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359\u201370.","journal-title":"Ann Neurol."},{"issue":"7","key":"1123_CR14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.5665\/sleep.5968","volume":"39","author":"C Ruoff","year":"2016","unstructured":"Ruoff C, Swick TJ, Doekel R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39(7):1379\u201387.","journal-title":"Sleep."},{"issue":"9","key":"1123_CR15","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.sleep.2015.05.013","volume":"16","author":"RK Bogan","year":"2015","unstructured":"Bogan RK, Feldman N, Emsellem HA, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102\u20138.","journal-title":"Sleep Med."},{"key":"1123_CR16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1100OC","author":"PK Schweitzer","year":"2018","unstructured":"Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial. Am J Respir Crit Care Med. 2018. \n                    https:\/\/doi.org\/10.1164\/rccm.201806-1100OC\n                    \n                  .","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1123_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.chest.2018.11.005","volume":"155","author":"PJ Strollo Jr","year":"2019","unstructured":"Strollo PJ Jr, Hedner J, Collop N, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study. Chest. 2019;155(2):364\u201374.","journal-title":"Chest."},{"issue":"Suppl. 22","key":"1123_CR18","first-page":"S232","volume":"84","author":"C Shapiro","year":"2018","unstructured":"Shapiro C, Schwab R, Pepin JL, et al. A long-term safety and maintenance of efficacy study of solriamfetol (JZP-110) for the treatment of excessive sleepiness associated with narcolepsy or obstructive sleep apnea [abstract no. M309]. Ann Neurol. 2018;84(Suppl. 22):S232\u20133.","journal-title":"Ann Neurol"},{"key":"1123_CR19","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals announces U.S. FDA approval of Sunosi\u2122 (solriamfetol) for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea [media release]. 20 Mar 2019. \n                    http:\/\/www.jazzpharmaceuticals.com\n                    \n                  ."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01123-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01123-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01123-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T23:27:23Z","timestamp":1588634843000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01123-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01123-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"6 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}